Smooth snack box: Yogurt, chia pudding, soft fruit
According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM
When a cancer patient can buy a 30-day supply of imatinib for $13.40 at Cost Plus instead of paying $2,500 at a retail chain, the patent defense that Novartis spent years constructing around that molecule stops mattering to that patient [1]
While animal studies have not shown direct harm to offspring, the absence of human lactation studies means healthcare providers typically recommend delaying GLP-1 treatment until breastfeeding ends
For patients on Ozempicparticularly those with underlying cardiovascular considerationsthese decongestants may warrant a provider consultation before use, especially at higher doses or longer durations
